Results 81 to 90 of about 75,041 (254)
Purslane Effect on GLP-1 and GLP-1 receptor in type 2 diabetes [PDF]
:Background: The aim of this study was to examine the effect of purslane seeds in glucagon-like peptide-1 concentration and glucagon-like peptide-1 receptor in women with diabetes.Methods: This was a quasi-experimental study. The population was consisted
Roja Daliri +3 more
doaj
A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders
Parkinsonian disorders, including Parkinson's disease, Lewy body dementia, multiple system atrophy, and progressive supranuclear palsy, are progressive neurodegenerative conditions with no treatment options to slow disease progression. This systematic review provides an overview of evidence of disease‐modifying therapies that have been evaluated in ...
Pepijn P.N.M. Eijsvogel +3 more
wiley +1 more source
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou +7 more
wiley +1 more source
Background and aim: Curcumin has shown significant cardiovascular protective effects. However, the low bioavailability limits its practical application. As a natural bioenhancer, piperine is expected to increase the bioavailability of curcumin, and then,
Xiao-jie Bai +7 more
doaj +1 more source
Peptide YY and Glucagon-like Peptide-1 Secretion in Obesity
Objective: The regulation of food intake is disturbed in obesity, possibly resulting from alterations in gut peptide secretion. We hypothesize that obesity is associated with attenuated systemic and tissue concentrations of the gut peptides PYY and GLP-1.
Jennifer Wilbrink +5 more
doaj +1 more source
Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi +6 more
wiley +1 more source
Sequeira et al. reveal how the glucagon‐like peptide‐1 receptor agonist (GLP‐1‐RA) semaglutide restores cardiomyocyte function in rats subjected to a high‐fat/high‐fructose diet (HFD). Employing fluorescence‐ and patch‐clamp technology in isolated cardiac myocytes, they demonstrate that semaglutide reverses HFD‐induced activation of L‐type calcium ...
Vasco Sequeira +12 more
wiley +1 more source
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source
Obesity is the one of the most important components of metabolic syndrome. Because obesity related hypertension accounts for two thirds of essential hypertension, managing obesity and metabolic syndrome is a crucial task in the management of hypertension.
Hae Young Lee +12 more
doaj +1 more source
Abstract Background Treatment with the sodium‐glucose co‐transporter 2 (SGLT2) inhibitor canagliflozin in insulin dysregulated (ID) horses has shown promising results in randomised clinical trials. Larger field studies are needed to further evaluate treatment responses and potential adverse effects under real‐world conditions.
Moa Hällbom +3 more
wiley +1 more source

